文献速递免疫规划传染病防控与疫情报告

辉瑞-BioNTech原始/BA.4-5二价疫苗与mRNA原始单价疫苗对有症状SARS-CoV-2感染保护作用的比较——法国匹配队列研究

Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
PubMed 文献 · Vaccine · 2023-08-03

法国匹配队列研究纳入136,852名≥60岁、2022年10月3日至11月6日接种加强针者,比较辉瑞-BioNTech原始/BA.4-5二价疫苗与mRNA原始单价疫苗对有症状Omicron BA.5感染的保护。中位随访77天,二价疫苗较单价疫苗额外保护8%(95%CI 0%-16%,p=0.045)。

要点

  • ≥60岁接种加强针者中,二价疫苗较单价疫苗对有症状Omicron BA.5感染的额外保护为8%(95%CI 0%-16%,p=0.045)。
  • 研究纳入136,852人,中位随访77天,采用Cox比例风险模型校正既往感染、年龄、性别及中风险合并症。
  • 结局为接种加强针≥7天后SARS-CoV-2 RT-PCR或抗原检测阳性且自报症状。

核心结论

  • 辉瑞-BioNTech原始/BA.4-5二价疫苗较mRNA原始单价疫苗对有症状Omicron BA.5感染提供8%的额外保护(95%CI 0%-16%,p=0.045)。

研究设计与样本

  • 匹配队列研究,纳入≥60岁、2022年10月3日至11月6日接种加强针者,按加强疫苗类型匹配,共136,852人,中位随访77天。

主要发现

  • 二价疫苗较单价疫苗对有症状Omicron BA.5感染的额外保护为8%(95%CI 0%-16%,p=0.045)。
  • 结局为接种加强针≥7天后SARS-CoV-2 RT-PCR或抗原检测阳性且自报症状。
  • 采用Cox比例风险模型校正既往感染、年龄、性别及中风险合并症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This cohort study evaluated the protection against symptomatic Omicron BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to mRNA Original monovalent vaccines (Pfizer- BioNTech or Moderna). Individuals of ≥60 years old, who received a booster dose between 03/10/2022 and 06/11/2022, when both bivalent and monovalent vaccines were used in France, were included and matched according to the type of booster vaccine received. The outcome of interest was a positive SARS-CoV-2 RT-PCR or antigenic test associated to self-reported symptoms, ≥ seven days after receiving the booster dose. Data were analysed with a Cox Proportional-Hazards model adjusted for the presence of previous infection, age, sex, and the presence of medium risk comorbidities. A total of 136,852 individuals were included and followed for a median period of 77 days. The bivalent vaccine conferred an additional protection of 8 % [95 % CI: 0 %-16 %, p = 0.045] against symptomatic Omicron BA.5infection compared to the monovalent vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Auvigne V, Tamandjou Tchuem CR, Schaeffer J, et al. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France. Vaccine. 2023. PMID: 37541823. doi:10.1016/j.vaccine.2023.07.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。